9 killed in US military cargo plane crash

Karachi, Jun 5: Pakistan's coronavirus cases rose to 89,249 on Friday after a record 4,896 new infections were detected in the country, while the death toll due to COVID-19 has reached 1,838, according to the health ministry.

The Ministry of National Health Service said that 68 patients died in the last 24 hours, taking the death toll to 1,838, whereas another 31,198 people have recovered.

It was the third consecutive day when a record number of cases were reported in Pakistan after the Eid holidays and easing of lockdown restrictions at the end of May.

Sindh province reported 33,536 infections, Punjab 33,144, Khyber-Pakhtunkhwa 11,890, Balochistan 5,582, Islamabad 3,946, Gilgit-Baltistan 852 and Pakistan-occupied Kashmir 299.

The authorities have conducted 638,323 tests, including a record 22,812 tests in the last 24 hours, the ministry said.

Despite the spike in number of COVID-19 cases, both houses of parliament are scheduled to meet separately on Friday. The Senate session started this morning while the National Assembly will be held in the afternoon, Radio Pakistan reported.

Chairman Senate Sadiq Sanjrani and Speaker National Assembly Asad Qaiser at a meeting at the parliament house in Islamabad reviewed arrangements made for the two sessions.

Fumigation was also carried out in the parliament house for the safety of the lawmakers and staff.

Earlier, the Opposition rejected the idea of virtual meetings and insisted that the sessions be held in person, noting that it was an important session of parliament because the budget is expected to be presented in the National Assembly in the next week.

The novel coronavirus which first originated from China's Wuhan city in December last year has claimed 391,249 lives and has infected over 6 million people globally, according to Johns Hopkins University data.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

New Delhi, Jan 8: Iran will welcome any peace initiative by India for de-escalating its tensions with the US after the killing of Iranian military commander Qasem Soleimani, the Iranian envoy here said on Wednesday.

His comments come hours after Iran launched missile strikes against two US military bases in Iraq in retaliation to the killing of its top commander General Qassem Soleimani.

"India usually plays a very good role in (maintaining) peace in the world. At the same time, India belongs to this region. We welcome all initiatives from all countries, especially India as a good friend for us, to not allow escalation (of tensions)," Iranian Ambassador to India Ali Chegeni told reporters after a condolence meeting for Solemani at the country's embassy here.

"We are not for war, we are looking for peace and prosperity for everybody in this region. We welcome any Indian initiative or any project that can help peace and prosperity in this world," he said.

On the Iranian attack on US targets in Iraq, Chegeni said his country retaliated under its right to defend.

Amid spiralling US-Iran tensions over the killing of Soleimani, External Affairs Minister S Jaishankar on Sunday had a conversation with his Iranian counterpart Javad Zarif and US Secretary of State Mike Pompeo, voicing India's concerns over the escalation of tensions.